Skip to content

Clinical trials

Melanoma trials in France

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Melanoma Country / region: France Clear all

342 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20012
20021
20033
20044
20056
20067
20072
20082
20099
20109
201114
201215
201322
20147
201523
201620
201721
201824
201922
202018
202125
202226
202318
202416
20258
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed173
Terminated54
Active, not recruiting42
Recruiting38
Unknown status28
Not yet recruiting3
Withdrawn3
No longer available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Bristol-Myers Squibb34
Novartis Pharmaceuticals18
Centre Hospitalier Universitaire de Nice15
GlaxoSmithKline14
Hoffmann-La Roche13
Assistance Publique - Hôpitaux de Paris12
Merck Sharp & Dohme LLC12
Pfizer12
European Organisation for Research and Treatment of Cancer - EORTC11
Nantes University Hospital11

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Melanoma342
Carcinoma, Non-Small-Cell Lung53
Neoplasms39
Neoplasm Metastasis26
Colorectal Neoplasms22
Skin Neoplasms21
Squamous Cell Carcinoma of Head and Neck21
Breast Neoplasms17
Carcinoma, Renal Cell17
Triple Negative Breast Neoplasms17

Trials

Showing 26 to 50 of 342. Each trial links to its page on Pharma Observatory.

242 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.